Steven on User Fees in Role Call Daily

Targeting FDA user fees would leave agency gutted, experts say

Steven Grossman, a regulatory consultant at HPS Group and author of the FDA Matters newsletter, said in an email to CQ Roll Call that his concerns about the future of the user fee program have grown since the Trump administration took over. 

“The risk of dramatically different medical product user fee programs — or none at all — has gone from blue (general risk) to at least yellow (significant risk),” he wrote. “If somebody suggested orange (high risk), I would not say they are exaggerating.” Read Full Article